De Pardieu Brocas Maffei advises the lenders on the entry of Motion Equity Partners in the share capital of Axience

De Pardieu Brocas Maffei has advised the debt funds managed by Cerea Partners, Groupama Asset Management, Muzinich and Schelcher Prince Gestion, on the acquisition of an equity stake in Groupe Axience by Motion Equity Partners, alongside its founder and CEO.

Founded in 2001, the Group develops and markets pharmaceutical and OTC products primarily for domestic pets, through its two brands Axience and Anidev.

The Group holds a leading position in its traditional segments, enabling it to cover all veterinarians’ needs. Positioned on highly dynamic and resilient markets, driven by favorable macro trends such as the increasing pet humanization, the Group aims at pursuing its strong growth to become the reference specialty vet pharma laboratory in Europe.